Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) has announced a virtual R&D event set for March 11, 2022, from 1:00 to 2:00 p.m. ET, focusing on the oral difelikefalin Phase 3 programs aimed at treating pruritus in patients suffering from atopic dermatitis and chronic kidney disease.

The event will feature key presenters, including CEO Christopher Posner and prominent medical professionals. A live audio webcast will be available on Cara's website, with a replay accessible afterward.

Presentation to highlight oral difelikefalin Phase 3 pruritus programs

STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual research and development (R&D) event on Friday, March 11, 2022, from 1:00 to 2:00 p.m. ET. The presentation will focus on the initiation of oral difelikefalin Phase 3 programs for the treatment of pruritus in patients with atopic dermatitis and non-dialysis dependent chronic kidney disease. An interactive Q&A session will follow the presentation.

Presenters will include:

• Christopher Posner, President & Chief Executive Officer and Director of Cara Therapeutics
• Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics
• Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY
• Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences

A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease. Phase 2 trials of oral difelikefalin are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What is the focus of the Cara Therapeutics virtual R&D event on March 11, 2022?

The event will focus on the initiation of oral difelikefalin Phase 3 programs for treating pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease.

Who are the presenters at the Cara Therapeutics event?

Key presenters include Christopher Posner, Joana Goncalves, Brian Kim, and Jonathan Silverberg.

How can I access the Cara Therapeutics presentation from March 11, 2022?

The presentation will be available as a live audio webcast on Cara's website, with a replay archived after the event.

What is difelikefalin and its significance for Cara Therapeutics?

Difelikefalin is Cara's novel treatment for pruritus, currently FDA-approved for use in patients with chronic kidney disease undergoing hemodialysis.

What preclinical trials are currently happening with difelikefalin?

Phase 2 trials of oral difelikefalin are ongoing for patients with primary biliary cholangitis and notalgia paresthetica.